Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw

J Transl Med. 2015 Jul 4:13:212. doi: 10.1186/s12967-015-0568-z.

Abstract

Background: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug effect linked to long-term and/or high-dose exposure to nitrogen-bisphosphonates (N-BP), the standard of care for the treatment of bone fragility disorders. The mechanism leading to bisphosphonate-associated ONJ (BAONJ) is unclear and optimal treatment strategies are lacking. Recent evidence suggests that BAONJ may be linked to drug-induced immune dysfunction, possibly associated with increased susceptibility to infections in the oral cavity. The objective of this investigation was to comprehensively assess the relationship linking immune function, N-BP exposure, the oral microbiome and ONJ susceptibility.

Methods: Leukocyte gene expression of factors important for immunity, wound healing and barrier function were assessed by real-time quantitative PCR and the oral microbiome was characterized by 454 pyrosequencing of the 16S rRNA gene in 93 subjects stratified by N-BP exposure and a history of ONJ.

Results: There were marked differences in the systemic expression of genes regulating immune and barrier functions including RANK (p = 0.007), aryl hydrocarbon receptor (AHR, p < 0.001), and FGF9 (p < 0.001), which were collectively up-regulated in individuals exposed to N-BP without ONJ relative to treatment controls. In contrast, the expression levels of these same genes were significantly down-regulated in those who had experienced BAONJ. Surprisingly, the oral microbiome composition was not directly linked to either BAONJ or N-BP exposure, rather the systemic leukocyte expression levels of RANK, TNFA and AHR each explained 9% (p = 0.04), 12% (p = 0.01), and 7% (p = 0.03) of the oral bacterial beta diversity.

Conclusions: The oral microbiome is unlikely causative of ONJ, rather individuals with BAONJ lacked immune resiliency which impaired their capacity to respond adequately to the immunological stress of N-BP treatment. This may be the common factor linking N-BP and anti-RANK agents to ONJ in at-risk individuals. Preventive and/or therapeutic strategies should target the wound healing deficits present in those with ONJ.

MeSH terms

  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / genetics
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / immunology*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / microbiology*
  • Diphosphonates / adverse effects
  • Disease Susceptibility / immunology
  • Disease Susceptibility / microbiology
  • Female
  • Gene Expression Regulation
  • Humans
  • Immunity*
  • Leukocytes / metabolism
  • Male
  • Microbiota / genetics
  • Microbiota / immunology*
  • Middle Aged
  • Mouth / microbiology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptor Activator of Nuclear Factor-kappa B / metabolism
  • Receptors, Aryl Hydrocarbon / genetics
  • Receptors, Aryl Hydrocarbon / metabolism
  • Wound Healing / genetics

Substances

  • Diphosphonates
  • RNA, Messenger
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Aryl Hydrocarbon
  • TNFRSF11A protein, human